AbbVie Company Profile

20:08 EST 18th December 2018 | BioPortfolio

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.

AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ approximately 21,000 people worldwide and market medicines in more than 170 countries.




Our antiviral program is focused on developing treatments for hepatitis C (HCV), a disease that affects more than 170 million people worldwide, with approximately 4 million people newly infected each year. HCV infections can potentially lead to long-term complications. AbbVie scientists are working to transform current treatment practices by investigating a new treatment regimen that is interferon-free for patients with genotype 1 HCV. We have several compounds for HCV in late-stage development, including protease, non-nucleoside polymerase, and NS5A inhibitors.


We are conducting innovative research on compounds that target receptors in the brain, which help regulate pain, mood, memory and other neurological functions. We have a number of early and advanced investigational compounds in human studies for conditions such as schizophrenia, chronic pain, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS) - all of which affect millions of people worldwide.


AbbVie's scientific experience with biologics serves as a strong foundation for continuing research in immunology. AbbVie is investigating a number of additional diseases, including spondyloarthropathies, hidradenitis suppurativa, and uveitis, all of which are in late-stage development. Our early discovery programs are focused on the investigation of both targeted oral therapies and biologics. AbbVie scientists are innovators in the antibody therapeutic field, with the creation and development of proprietary Dual-Variable Domain immunoglobulins (DVD-Ig), which allows for creating combination antibodies to simultaneously target multiple pathways responsible for disease progression.

AbbVie's DVD-Ig technology allows us to target multiple disease-causing antigens with a single biologic agent. This is critical to our discovery process.


Our oncology research is focused on the discovery and development of targeted therapies that work against the processes cancers need to survive. We are investigating both small- and large-molecule approaches, and our internal research efforts are balanced with external collaborations across industry, academia, and government. AbbVie's oncology pipeline includes multiple new molecules in clinical trials, being studied in more than 15 different cancers and tumor types, including some of the most widespread and difficult-to-treat cancers such as multiple myeloma and chronic lymphocytic leukemia.


Chronic kidney disease (CKD), the progressive loss of kidney function, affects 50 million people in the U.S. and Europe alone. CKD is on the rise, driven by higher rates of diabetes, obesity and hypertension. AbbVie's renal care pipeline includes potential therapies for CKD and for acute kidney injury, a complication of major surgery that affects 1.2 million people at risk annually.


AbbVie is currently focused on developing a compound for endometriosis and uterine fibroids, which each affect more than 16 million women worldwide. Both are highly prevalent conditions associated with a number of symptoms including pain and infertility. Because these conditions are undertreated, we have the potential to fill a significant therapeutic void


1 North Waukegan Road
North Chicago

News Articles [544 Associated News Articles listed on BioPortfolio]

AbbVie: A commitment to sustainable healthcare

AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Project Director, Oncology Development at AbbVie, discusses wit...

AbbVie, Momenta settle litigation surrounding Humira biosimilar

AbbVie Inc. and Momenta Pharmaceuticals Inc. have settled global patent litigation surrounding M923 (adalimumab), Momenta’s proposed biosimilar of AbbVie’s Humira. Under the agreement, AbbVie gran...

AbbVie And Mylan Announce Humira Patent License

NewsUnder the terms of the agreements, AbbVie will grant Mylan a non-exclusive license on specified dates to AbbVie's intellectual property relating to Humira in the U.S. and in various other countrie...

AbbVie Resolves Humira Patent Disputes with Sandoz

NewsUnder the terms of the settlement agreements, AbbVie will grant to Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira.

AbbVie sues NHS over hep C drug procurement scheme

American pharma firm AbbVie is taking NHS England to court over a procurement process aimed to help England become the first country in the world to eradicate the hepatitis C virus (HCV).  AbbVie st...

Mylan signs U.S. license deal on Humira with AbbVie

AbbVie Inc said on Tuesday it signed a U.S. licensing deal with Mylan NV for its proposed biosimilar to AbbVie's blockbuster drug Humira, in a move that will give it more near-term control over the co...

Venclexta: what’s next for AbbVie’s first-in-class drug?

On June 11, AbbVie and Roche announced the FDA’s approval of Venclexta (venetoclax) in combination with Rituxan (rituximab) for the...Read More... The post Venclexta: what’s next for AbbVie’s fi...

AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away

What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos' cystic fibrosis portfolio i...

Drugs and Medications [0 Results]


PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Comprehensive Long-Term Safety of Adalimumab from Eighteen Clinical Trials in Adult Patients With Moderate to Severe Plaque Psoriasis.

Adalimumab (Humira ; AbbVie Inc., USA) is a fully human monoclonal antibody specific for tumour necrosis factor-α approved to treat adults with moderate-to-severe chronic plaque psoriasis.

Elagolix: First Global Approval.

Elagolix (ORILISSA™), an orally bioavailable, second-generation, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist, is being developed AbbVie and Neurocrine Biosciences for the t...

Delayed return to estrus following treatment with the gonadotrophin-releasing hormone agonist, Lucrin Depot, in the tammar wallaby.

Gonadotrophin-releasing hormone agonists that induce a reversible contraceptive state in several marsupials have the potential to be used to synchronize estrus. We used a model macropod, the tammar wa...

Elagolix for endometriosis: all that glitters is not gold.

Elagolix, an orally active non-peptidic GnRH antagonist, has been approved by the Food and Drug Administration for the management of moderate to severe pain associated with endometriosis. As the degre...

Clinical Trials [24 Associated Clinical Trials listed on BioPortfolio]

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures

The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie adults with chronic hepatitis C virus ("HCV"), who have not responded to prior treatment with p...

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis, in the Portuguese National H

This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study

The interferon-free combination regimen of Paritaprevir/r - Ombitasvir with or without Dasabuvir (ABBVIE REGIMEN) ± Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been...

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

The purpose of this study is to evaluate the efficacy and safety of co-administration of ABT-493/ABT-530 plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT)...

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

The interferon-free combination regimen of Paritaprevir/r - Ombitasvir with or without Dasabuvir (ABBVIE REGIMEN) ± Ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been...

Companies [6 Associated Companies listed on BioPortfolio]


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. AbbVie combines the focus and passion of a leading-edge biotech with the exp...

Alector, Inc.

Alector is a privately owned biotechnology company whose mission is to develop therapies that harness the immune system to treat neurodegenerative diseases and cancer. Alector was...

Jnana Therapeutics Inc.

Jnana Therapeutics is a biotechnology company creating the first drug discovery platform to unlock the solute carrier (SLC) family of metabolite transporters as a therapeutic targ...

Palleon Pharmaceuticals

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Pl...

Synlogic™ Inc.

Synlogic™ is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, pioneering the development of a novel class of therapeutics, called Synthetic Bioti...

More Information about "AbbVie" on BioPortfolio

We have published hundreds of AbbVie news stories on BioPortfolio along with dozens of AbbVie Clinical Trials and PubMed Articles about AbbVie for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AbbVie Companies in our database. You can also find out about relevant AbbVie Drugs and Medications on this site too.

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Corporate Database Quicklinks

Searches Linking to this Company Record